Transcript Feasible to map subtle brain changes

Paul’s Slides for George -to put in IMAGING CORE for
ADRC EAB meeting
Summary
We developed 4 major new methods to track
brain change, e.g. Alzheimer’s disease or MCI
progression
Can now map disease spreading in the living
brain (cortical thickness video maps,
fluid maps of brain change - TBM)
Feasible to map subtle brain changes (~0.5%
volume loss) in an individual over 2-4 weeks
Now testing in large trials to distinguish drug
effects (galantamine, lithium, antipsychotics)
Cortical Thickness Mapping (used in ~30 papers)
- see Thompson et al., 2004 (for an overview)
Example: AIDS Dementia Complex
(Thompson et al., Proc. Nat. Acad. Sci., 2005)
Also began to correlate cortical thickness on MR
with FDG-PET in healthy controls and AD (Thompson/Huang/Small)
Who did we train to use
our tools?
• Univ. of Pittsburgh ADC (PI: Oscar Lopez) began to use our HP/CTX
methods and have submitted ~10 papers on MCI and AD (N=381),
HIV-associated dementia (N=53), and semantic dementia. One was
in PNAS this month (Thompson et al., 2005)
• Liana Apostolova MD, ADRC, Asst. Prof. (journal papers submitted
on cortical thinning in MCI, relation to apathy, hippocampal atrophy in
MCI, several in preparation)
• Giovanni Frisoni, Rome, Italy -- submitted several papers using our
hippocampal/cortex mapping methods
• Mony de Leon, NYU (learning surface-based PET analysis)
• Addition of large longitudinal datasets (G. Bartzokis), presenilin
subjects (J. Ringman), ADNI (M. Weiner/C. Jack - analysis of 200
prep phase scans is now submitted to NeuroImage; not ADRC but
further validated methods)
• Began PET-MRI work correlating MRI thickness with FDG-PET in G.
Small’s ApoE genotyped normals (N=30 approx., to date; also
FDDNP, MPPF; N=6-10; data will be submitted to HBM, Dec 05)
Large-scale automated 3D ventricular mapping
in elderly controls, MCI, AD
(N=381; Thompson/UCLA/U. Pittsburgh)
How Can We Best Track
Neurodegenerative Brain
Change in an Individual?
Thompson et al., Nature 404:190-193 (2000).
Case Study: Mapping Atrophy in a Semantic Dementia Patient
Thompson/Glaxo study
Changes Internal to the Basal Ganglia
in a Semantic Dementia Patient (Case Study)
Automated Mapping
of
Trajectory of WM
Atrophy
over time
in a Patient with
progressive posterior
cortical atrophy and
Broca’s area atrophy
(Case Study;
P. Thompson et al./U.
Queensland/Glaxo)
Promising Biomarker
for Trials
Summary
New methods to track brain change, e.g.
Alzheimer’s disease progression
Can now map disease spreading in the living
brain (cortical thickness video maps,
fluid maps of brain change)
Now testing in large trials to distinguish drug
effects (galantamine, lithium, antipsychotics)
Feasible to map subtle brain changes (~0.5%
volume loss) in an individual over 2-4 weeks